Vaccination With RA 27/3 Rubella Vaccine

Abstract

Eighteen children who had been successfully immunized two years previously with RA 27/3 rubella virus vaccine (either subcutaneously or intranasally) were examined for persistence of antibodies and resistance to intranasal challenge with "wild" virus (Brown strain). Hemagglutination inhibition (HI), complement fixation (CF), and anti-\g=q\precipitating antibodies showed marked stability with no significant decline in titer during the two-year period; the differential fluorescent antibody (FA) test indicated that all children possessed antibody with the vaccine FA marker at the time of

Untitled

“…Nonetheless, the rubella E1 protein ties to myelin oligodendrocyte glycoprotein (MOG) and ectopic articulation of MOG on non-tolerant cells consider in-vitro infection. MOG is a cell receptor, particularly for maternal diseases that spread to the hatchling 21 . There is an abnormal state of homology between rubella E2 protein and MOG, which could clarify the capacity of antibodies against rubella to cause demyelination of rodent cerebrum cells.…”

Prevention of Congenital Rubella

“…A disturbing trait of the rubella vaccines currently available in Canada is their inability to protect against wild virus infection for any appreciable length of time.6 A newer vaccine, RA 27/3, prepared in human WI-38 cells, appears to be antigenically more complete than either HPV-77 or Cendehill strain vaccines.79 RA 27/3 also results in a higher rate of conversion to seropositive than either HPV-77 or Cendehill strain vaccines10 and is associated with a relatively low rate of reinfection by wild virus.11 The reinfection rate for other commonly used attenuated vaccine strains has been found to be significantly higher; for the Cendehill strain it was over 50% only 2 years after vaccination, and for RA 27/3 it was 9% (comparable to the reinfection rate following natural immunization).12 The immunity induced by RA 27/3 appears to be similar to natural immunity. 13 The overall advantages have been extensively reviewed by Plotkin, Farquhar and Ogra.11 The side effects associated with this vaccine appear to be no greater than those associated with other vaccine strains11 and RA 27/3 therefore appears to be overwhelmingly the vaccine of choice. At the time of writing it has been licensed for use in the US; although it is not yet licensed for use in Canada, licensing is anticipated in the near future.…”

“…This includes all such female staff in any children's hospital, obstetric and gynecologic unit, nursery and school (see below). 13. Is there anyone who should not receive rubella vaccine?…”